OctoPlus' licensee Biolex presents final Phase IIb results at EASL highlighting tolerability advantages of Locteron in treatment of HCV

04-Apr-2011 - Biolex announced that final 72-week results from its SELECT-2 Phase 2b trial of Locteron® for the treatment of hepatitis C are being presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany. Data presented today show that Locteron ...

OctoPlus announces publication of key Phase IIb results for Locteron

01-Nov-2010 - OctoPlus N.V. announces that its licensee Biolex Therapeutics has published positive interim results at week 60 of the Phase IIb trial, 12 weeks after completion of 48 weeks of treatment with Locteron®. The results are consistent with the existing clinical results for Locteron and confirm ...

OctoPlus' licensee Biolex commences Phase IIb study with Locteron

22-Apr-2009 - OctoPlus N.V. announced that its licensee Biolex Therapeutics has commenced patient dosing in the SELECT-2 Phase IIb clinical study of Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron combines OctoPlus' controlled release drug ...

OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C

16-Oct-2007 - OctoPlus N.V. announced the successful completion of the Phase IIa clinical study with its lead product Locteron(TM), a controlled release interferon alfa product for the treatment of chronic hepatitis C (HCV). According to the company, results from this study confirm Locteron's potential to ...

OctoPlus announces promising results for Locteron Phase IIa clinical study

30-Jul-2007 - OctoPlus N.V. announced positive initial results of the ongoing SELECT-1 Phase IIa study with its lead product Locteron(TM) , a controlled release interferon alfa for the treatment of chronic hepatitis C (HCV). In the 12-week Phase IIa study, the combination of the highest dose of Locteron ...

OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C

01-Feb-2007 - OctoPlus N.V. announced the commencement of a Phase IIa study with LocteronTM, its controlled release formulation of alfa interferon for treatment of chronic hepatitis C. The Phase IIa study is designed to evaluate Locteron in combination with the anti-viral drug ribavirin in previously untreated ...

Biolex Forms Broad Strategic Alliance with Centocor to Develop and Manufacture Therapeutic Proteins

19-Apr-2005 - Biolex, Inc. announced a broad-based, multi-leveled strategic alliance with Centocor, Inc. to manufacture selected proteins using the Biolex LEX System(TM). The alliance will leverage certain key product candidates in Centocor's therapeutic protein pipeline, using Biolex' innovative method to ...

Biolex Acquires Epicyte Pharmaceutical

Combination creates powerful monoclonal antibodies capabilities

07-May-2004 - Pittsboro, N.C. -- Biolex, Inc., a privately held protein therapeutics company, has acquired Epicyte Pharmaceutical, Inc., a privately held, San Diego-based company focused on the discovery and development of human monoclonal antibodies (mAbs). The combination creates powerful mAbs capabilities ...